Inhibition of aberrantly active DDR signaling pathway has become an attractive therapeutic strategy in cancer therapy with highly selective small molecule inhibitors of ATM and ATR signaling in preclinical and clinical development, respectively [70]. Here, ATR is linked to cancer.